ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
Roche Holding AG Akt-0.06% CHF238.35B ...
After hours: February 14 at 6:02:49 PM EST Loading Chart for VTYX ...
After hours: February 14 at 7:59:52 p.m. EST Loading Chart for TNXP ...